Studie zeigt überraschenden Trend bei Ozempic-Anwendern, die weniger Dosen als üblich einnehmen. Die Ergebnisse deuten darauf hin, dass GLP-1-Anwender durch eine schrittweise Reduzierung ihre Arztkosten senken und gleichzeitig ihren Gewichtsverlust aufrechterhalten können.

>Sometimes a little goes a long way. That just might be true when it comes to taking GLP-1 treatments like semaglutide (Ozempic and Wegovy) for weight loss, recent research finds.

>Doctors at Scripps Health studied the outcomes of people who switched to a reduced dosing schedule of their GLP-1 therapy. They found that people generally maintained their weight loss and other improved health markers, even if they dosed as little as once every two months. Though still preliminary, the results suggest it could be easier and more affordable to stay on GLP-1s long-term than is currently assumed.

>“These findings support structured de-escalation as a promising strategy to reduce treatment burden without sacrificing efficacy,” the authors wrote in their paper, [published](https://onlinelibrary.wiley.com/doi/full/10.1002/oby.70137) last week in the journal Obesity.

honestly kinda surprised this works but good to know we don’t have to choose between being broke and gaining it all back.